APLM stock forecast, quote, news & analysis
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer... Show more
Why Apollomics (APLM) Stock Is Down -14.7% in the Last 30 Days
Key Takeaways
- APLM declined roughly 14.7% over the trailing 30 days, from a close of $23.27 on September 28, 2026, to $19.85 on October 27, 2026.
- The pullback follows a sharp summer rally that carried shares from about $14 in early June to an intraday high above $28 in early September.
- Over the trailing three months, APLM is still up about 9.7%, reflecting the earlier advance tied to regained Nasdaq compliance and a $10 million private placement.
- The recent weakness reflects a lack of near-term catalysts, fading momentum from the August capital injection, and dilution from newly issued shares.
- Clinical progress on the lead candidate vebreltinib (APL-101) and the next quarterly earnings update remain the key fundamental drivers to monitor.
- As a micro-cap with a market capitalization near $58 million and limited trading liquidity, APLM can experience outsized price swings.
- For deeper data on this ticker, review Apollomics' Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to see how automated trading strategies are positioning across the market.
Apollomics (APLM) Company Overview and Market Position
Apollomics Inc. (NASDAQ: APLM) is a Foster City, California-based clinical-stage biopharmaceutical company focused on discovering and developing oncology therapies for difficult-to-treat and treatment-resistant cancers. Founded in 2015, the company uses targeted therapeutics and immuno-oncology approaches designed to inhibit specific molecular pathways and improve tumor-cell recognition.
Apollomics' lead program is vebreltinib (APL-101), an oral, selective c-Met inhibitor being evaluated in a Phase 2 multicohort clinical trial for non-small cell lung cancer and other advanced tumors with c-Met alterations. The candidate has received orphan drug designation from the U.S. Food and Drug Administration. As a pre-revenue, late-stage developer, the company has no approved products and depends on clinical results, collaboration and licensing arrangements, and continued financing.
Apollomics (APLM) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, APLM fell from $23.27 at the close on September 28, 2026, to $19.85 at the close on October 27, 2026, a decline of approximately 14.7%. The move was not a straight line lower: shares held near $21 to $23 through most of October before a high-volume session on October 26, when the stock dropped to $19.85 on roughly 42,000 shares traded, one of the heaviest volume days of the period.
The picture looks different over the trailing quarter. From a close of $18.09 on July 28, 2026, shares climbed to an intraday peak above $28 in early September before giving back ground, leaving the stock up about 9.7% over the three-month span. In short, the quarterly gain was driven almost entirely by a summer surge, while the past 30 days have represented a period of consolidation and retreat.
What Drove APLM Stock Price in the Last 30 Days
The recent decline appears driven more by a thinning of positive catalysts than by any single negative event. After the August private placement and the earlier resolution of its Nasdaq listing deficiency, Apollomics entered a stretch with fewer imminent news triggers, and momentum from the summer capital raise tapered. Investor concerns also centered on equity dilution: the $10 million private placement involved the issuance of up to roughly 700,000 Class A ordinary shares, expanding the share count and weighing on sentiment.
Trading conditions amplified the move. APLM is a thinly traded micro-cap with average daily volume often measured in the low thousands of shares, so relatively modest selling pressure can produce sharp percentage swings. Market data aggregators also pointed to cautious analyst posture, with a consensus "Sell" rating cited in recent coverage even as one provider upgraded the stock to "Hold." These factors, combined with a lack of fresh clinical or financial announcements during the month, left the stock vulnerable to profit-taking after the summer run.
What Drove APLM Stock Performance Over the Last Quarter
The broader three-month trend was defined by two positive corporate developments. First, Apollomics regained full Nasdaq listing compliance in July 2026 after addressing a minimum market-value deficiency, removing a near-term delisting overhang. Second, in August the company announced a $10 million private placement combining approximately $8 million in cash at $15.00 per share with the conversion of a $2 million convertible note held by Chairman and CEO Hung-Wen (Howard) Chen at $12.00 per share.
Management also signaled confidence through open-market purchases, with insiders acquiring roughly 583,000 shares valued near $8.25 million over a 90-day window. These catalysts helped drive the rally from about $18 in late July to the early-September peak. The subsequent 30-day pullback reflects a normalization from that spike rather than a reversal of the underlying capital and listing milestones.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's AI-powered trading bots. While Tickeron offers hundreds of automated bots that collectively trade thousands of tickers, only the top-performing and most relevant strategies are highlighted in this section. Each bot varies in trading style, holding timeframe, and performance metrics, allowing users to compare approaches rather than relying on a single signal. The page is designed to help traders evaluate how algorithmic strategies are behaving in current market conditions. For investors following volatile micro-cap names like Apollomics, reviewing these automated strategies can add a data-driven perspective to manual research.
APLM Stock Forecast Drivers: What Investors Should Watch Next
Several factors are likely to shape APLM in the coming periods. The next quarterly earnings report will be closely watched for updates on cash runway, operating expenses, and the pace of spending, given the company's reliance on external financing. Clinical milestones for vebreltinib (APL-101), including any trial data or regulatory updates, remain the central long-term driver. Investors should also monitor the resolution of the company's terminated collaboration and licensing agreement with its Asia-based partner LaunXP, a dispute involving a claimed unpaid balance of approximately $3.8 million, which is subject to dispute-resolution procedures. Finally, dilution risk, financing activity, and the micro-cap's low liquidity will continue to influence day-to-day price volatility.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
APLM in -16.20% downward trend, sliding for three consecutive days on November 05, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where APLM declined for three days, in 223 of 249 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on APLM as a result. In 74 of 105 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 70%.
The Moving Average Convergence Divergence Histogram (MACD) for APLM turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 26 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 54%.
The 10-day moving average for APLM crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for APLM entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where APLM's RSI Oscillator exited the oversold zone, 18 of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where APLM advanced for three days, in 140 of 176 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
APLM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. APLM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 48 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.704) is normal, around the industry mean (3.498). P/E Ratio (-1.287) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (3.761) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. APLM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology